TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00223691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: 5-50 µg, S.C. Single dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water intake
Description: Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine Hydrochloride
Description: 12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine HCL
Description: 150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: 5 - 40 mg PO. Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergotamine/ Caffeine
Description: Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 50-200 mg PO. Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: 15, 30 or 60 mg, PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 or 10 mg PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 25, 50 or 75 mg, PO. Singe dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 300, 600 or 900 mg, PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.05% nasal solution
Description: 1-2 sprays/ nostril. Single dose.
Study: NCT04282824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monosodium Glutamate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT00006349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04019509

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood test
Description: blood test for thyroid antibodies and thyroid function (TSH, FT4)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood test
Description: blood test for thyroid antibodies and thyroid function (TSH, FT4)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood test
Description: blood test for thyroid antibodies and thyroid function (TSH, FT4)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: follow up treatment outcome
Description: questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: follow up treatment outcome
Description: questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: follow up treatment outcome
Description: questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
Study: NCT02432950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participate in the PNP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in the PNP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01099059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine 100-150 mg depending on weight (100 mg/day for \<30 Kg and 150 mg/day for \>30 Kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritalin
Description: ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)
Study: NCT03026972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose adjuvant
Description: Population I and polulation IV are coxal muscle injection of low dose adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose adjuvant
Description: Population I and polulation IV are coxal muscle injection of low dose adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adjuvant
Description: Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adjuvant
Description: Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adjuvant
Description: Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose vaccine
Description: Population I and population IV are coxal muscle injection of low dose vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose vaccine
Description: Population I and population IV are coxal muscle injection of low dose vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose vaccine
Description: Population II,population III and population IV are coxal muscle injection of high dose vaccine .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose vaccine
Description: Population II,population III and population IV are coxal muscle injection of high dose vaccine .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose vaccine
Description: Population II,population III and population IV are coxal muscle injection of high dose vaccine .
Study: NCT01661179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib 300mg
Description: 300 mg oral dose once daily (100 mg x 3 tablets)
Study: NCT00321737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, orally, once daily for up to six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study: NCT00145639

Intervention type: DRUG
Group type: OTHER
Intervention: Ifosfamide, Carboplatin, Doxorubicin
Description: See Detailed Description for treatment plan.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Limb Sparing
Description: See Detailed Description for treatment plan.
Study: NCT03542084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsolicited endocrine e-consult
Description: The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
Study: NCT04715360

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous activated platelet-rich plasma
Description: Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient

Intervention type: DRUG
Group type: OTHER
Intervention: Avigan
Description: Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avigan
Description: Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
Study: NCT06309446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoralan Wound
Description: Topical application of approximately 0.2 g per test field (approx. 1.2 cm in diameter each) once daily during a 12-day treatment period (11 treatments).
Study: NCT00713687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)
Description: 1. Photodynamic therapy (PDT) after successful drainage:~   Photosan® 2 mg/kg i.v. 48 hrs before laser activation~2. 9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~   * Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~  * Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~  * iteration every 14 days~  * afterwards 4 weeks intermission~3. Iteration of 1. and 2. in case of good compatibility
Study: NCT03694587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg TEPI Medicated Plaster
Description: Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
Study: NCT00223691

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovril
Description: 6-10 g, PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine tartrate
Description: 1.5-6 mg PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Description: 10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inflatable abdominal binder
Description: External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
Study: NCT01681966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF110- oily solution (Ropivacaine)
Description: Post operative application of PRF110-oily solution (Ropivacaine)
Study: NCT03096275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
Study: NCT00223691

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: inflatable abdominal binder (sham)
Description: External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
Study: NCT03110198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone sodium succinate
Description: hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
Study: NCT01310010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
Study: NCT01071954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection once a week.
Study: NCT03097289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel system
Description: A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
Study: NCT00501644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC of 5 by 1 hour IV infusion every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma
Description: 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
Study: NCT02835469

Intervention type: DRUG
Intervention: Menotrophin
Study: NCT03096275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CYC
Description: Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
Study: NCT03794973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TOL-3021
Description: TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TOL-3021 Placebo
Description: TOL-3021 Placebo
Study: NCT00823173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESBA105
Description: ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
Study: NCT01749488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designated dietitian for the ward
Description: This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
Study: NCT02803203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02024854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Study: NCT01814956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplus 20%
Description: Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
Study: NCT03694587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aktren® 200 mg überzogene Tabletten (Ibuprofen)
Description: one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
Study: NCT04076475

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: neuromuscular electrical stimulation
Description: Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
Study: NCT03110198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine with hydrocortisone sodium succinate
Description: Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
Study: NCT03833375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Shared-decision making tool
Study: NCT01480479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rindopepimut (CDX-110) with GM-CSF
Description: Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KLH
Description: Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
Study: NCT04370964

Intervention type: OTHER
Group type: OTHER
Intervention: Lausanne Trilogy Play
Description: Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together.

Intervention type: OTHER
Group type: OTHER
Intervention: Lausanne Family Play
Description: Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
Study: NCT00371111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of Triamcinolone
Description: 4 mg of Triamcinolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of Avastin
Description: Injection of 1.25 mg of Avastin and
Study: NCT03430583

Intervention type: DRUG
Intervention: MZ101
Description: Drug
Study: NCT00866892

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: irrigation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No irrigation
Description: no irrigation
Study: NCT00556192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period.
Study: NCT03789890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
Study: NCT04720495

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One stage ridge splitting with simultaneous implant placement
Description: A full mucoperiosteal flap was raised using the sharp periosteal elevator to expose the bone crestally and buccally.~An inverted U-shaped bone cut, down to the cancellous bone, was done in the undercut area with a piezoelectric device.~The horizontal bone cut was made apical to the most concave point in the undercut area with a distance of 3 mm.~The two vertical bone cuts were placed at least 1 mm away from the adjacent roots and extended beyond the undercut area.~The released bone end was minimally elevated using a periosteotome through a greenstick fracture.~All implants were installed with the implant shoulders flush to the bone level using a low-speed drilling procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage ridge splitting with implant placement
Description: The first surgery is the same as one stage ridge splitting Four weeks later, after revascularization between the bone block and the mucoperiosteum, the second surgery will be performed.~A crestal incision was done and the envelope flap slightly elevated to preserve the blood supply.~The implants will be placed in the same manner as one stage ridge splitting